A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults Living with HIV in Eswatini
-
Filter
-
U
- All Projects
- Current
- Upcoming
- Past
- Multi-Country
-
Country +
- Angola
- Bahrain
- Belarus
- Botswana
- Brazil
- Bronx
- Burkina Faso
- Burundi
- Cameroon
- Central Asia
- China
- Colombia
- Colombia and Peru
- Congo Brazzaville
- Cote d’ Ivoire
- Democratic Republic of the Congo
- Dominican Republic
- Egypt
- El Salvador
- Eswatini
- Eswatini CTU
- Ethiopia
- Georgia
- Ghana
- Guatemala
- Haiti
- Harlem
- Honduras
- India
- Kazakhstan
- Kenya
- Kyrgyz Republic
- Kyrgyzstan
- Lesotho
- LesothoMalawi
- Liberia
- Malawi
- Mali
- Mauritania
- Mozambique
- Myanmar
- Namibia
- Nigeria
- Panama
- Peru
- Philippines
- Russia
- Rwanda
- Senegal
- Sierra Leone
- South Africa
- South Sudan
- Tajikistan
- Tanzania
- Thailand
- Uganda
- Uganda Refugees
- Ukraine
- United States
- Uzbekistan
- Vietnam
- Zambia
- Zimbabwe
Status
Upcoming
Locations
Eswatini CTU
Our Approach
Research
Health Challenges
HIV/AIDS
Keywords
HPV